Rue du Bois Saint Jean 15/1
BCE / VAT: BE 0521.816.349
Syngulon develops antibiotic-free technologies for use in so-called “micro-refineries”, microbial cells that have been engineered to produce industrially relevant compounds. These technologies incorporate bacteriocins into the biofermentation process by two applications:
Selection for the desired producing microbe.
Prevention of contamination, by undesired mutants or external microbes.
In both cases, clients using our systems for both selection and prevention have observed an increase in product yield.
Poster presented at PEGS 2018 The Essential Protein Engineering Summit in Boston, MA (USA)
This presentation outlines Syngulon’s bacteriocin-based selection technology for selecting recombinant proteins in a biofermenter. It outlines our intellectual property (US Patent 9,333,227 and a second recently filed patent). Importantly, it shows actual results for a current client demonstrating an increase in the production of a 40 kDA recombinant protein (Protein X) not only at a final concentration, but also temporally. This shows that our system not only removes the use of antibiotics for selection, but also increases desired protein yield.
Presentation on “Bacteriocins applications for the development of new genetic control of microbial strains in industrial fermentation” at BIOKET 2018 in Strasbourg, France
This presentation outlines similar information to the first, but goes into greater detail regarding Syngulon’s philosophy, as well as detailing bacteriocin genetic and chemical structure, in vivo and in vitro synthesis, and shows results of bacteriocin activity. It presents Syngulon’s R&D project with Tereos, the leading producer of sugar in France and third in the world.